Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Yimmugo in Primary Immunodeficiency Disease
NCT02810444Phase 3Completed
- Sponsor
- Biotest AG
- Start
- Oct 2016
- Primary completion
- Apr 2020
- Modality
- Biologic
- Countries
- 5
01
Overview
A Phase 3 trial of polyvalent human immunoglobulin in primary immunodeficiency disease (PID), sponsored by Biotest AG. Started Oct 2016; status: completed.
02
Drugs
polyvalent human immunoglobulin
03
Conditions
primary immunodeficiency disease (PID)
Beyond the preview
Go deeper on NCT02810444.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02810444.